News
That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...
Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.
Weight loss drugmaker Novo Nordisk (NVO ... was made in light of the company’s recent market challenges and the performance of its stock since mid-2024. Jørgensen has agreed to serve as ...
Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...
Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024. Increased competition from compounded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback